Skip to main content

Hydrops Fetalis

0
Pipeline Programs
2
Companies
2
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

2 companies ranked by most advanced pipeline stage

Human BioSciences
Human BioSciencesWV - Martinsburg
1 program
Exome sequencingN/A1 trial
Active Trials
NCT03412760Active Not Recruiting500Est. Feb 2027
Pediatrix Therapeutics
Pediatrix TherapeuticsChina - Shanghai
1 program
Tandem MS test for inborn errors of metabolismN/A1 trial
Active Trials
NCT00143039Terminated48Est. Aug 2009

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
Human BioSciencesExome sequencing
Pediatrix TherapeuticsTandem MS test for inborn errors of metabolism

Clinical Trials (2)

Total enrollment: 548 patients across 2 trials

Hydrops: Diagnosing & Redefining Outcomes With Precision Study

Start: Oct 2018Est. completion: Feb 2027500 patients
N/AActive Not Recruiting
NCT00143039Pediatrix TherapeuticsTandem MS test for inborn errors of metabolism

Amniotic Fluid Tandem Mass Spectrometry for Pregnancies Complicated by NIH and Severe Symmetrical IUGR

Start: Mar 2006Est. completion: Aug 200948 patients
N/ATerminated

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

2 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.